title: The PulmoSphere™ platform for pulmonary drug delivery.
abstract: Spray-dried PulmoSphere™ formulations comprise phospholipid-based small, porous particles. Drug(s) may be incorporated in or with PulmoSphere formulations in three formats: solution-, suspension-, and carrier-based systems. The multiple formats may be administered to the respiratory tract with multiple delivery systems, including portable inhalers (pressurized, metered-dose inhaler and dry-powder inhaler), nebulizers, and via liquid dose instillation in conjunction with partial liquid ventilation. The PulmoSphere platform (particles, formats, delivery systems) enables pulmonary delivery of a broad range of drugs independent of their physicochemical properties and lung dose. The engineered particles provide significant improvements in lung targeting and dose consistency, relative to current marketed inhalers.
authors.affiliation: Novartis Pharmaceuticals Corporation, San Carlos, CA 94070, USA.
authors.forename: Jeffry
authors.initials: J
authors.lastname: Weers
authors.forename: Thomas
authors.initials: T
authors.lastname: Tarara
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D006801:Humans; D008956:Models, Chemical; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry; D010743:Phospholipids / Q000737:chemistry*; D016062:Porosity; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000336:Aerosols; D004337:Drug Carriers; D004364:Pharmaceutical Preparations; D010743:Phospholipids